Dr. Wildon Farwell reports

SATELLOS ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 2 PEDIATRIC STUDY OF SAT-3247 FOR DUCHENNE MUSCULAR DYSTROPHY

The first participant has been dosed in Satellos Bioscience Inc.'s Basecamp, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy (DMD).

The study will evaluate SAT-3247 in 51 ambulatory children with DMD aged seven, eight or nine years of age. Primary end points include safety, tolerability and effect on muscle force. Secondary end points will assess SAT-3247's impact on muscle quality, function and regeneration.

"Designed as a potential pivotal trial, Basecamp marks a significant step for Satellos in evaluating the therapeutic potential of SAT-3247 in children living with Duchenne," said Satellos co-founder and chief executive officer Frank Gleeson. "Data generated from Basecamp could play a meaningful role in accelerating the development of SAT-3247 as a novel treatment for this disease."

The Basecamp trial is actively enrolling, and Satellos plans to establish 25 sites for the study at clinical centres in the United States, Europe, the United Kingdom, Australia, Canada and Serbia.

"Basecamp will focus on an important period in Duchenne when muscle health and function begin to decline more rapidly," said Satellos chief medical officer Wildon Farwell, MD. "Treatment options remain limited for this devastating disease, and this study will evaluate a novel approach to potentially increase muscle regeneration and thereby improve function among children with Duchenne."

ABOUT SAT-3247

SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status.

About Satellos Bioscience Inc.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem cell signalling that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities.

We seek Safe Harbor.